Blood Disorders Overtake Cancer On EMA’s PRIME Scheme

 
• By Neena Brizmohun

uniQure has become the third company to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme for a gene therapy for hemophilia, making hematology-hemostaseology the most common therapeutic areas for products on the scheme.

RedBloodCellsOnWhite_1200x675
Another drug for a blood disorder has made it on the EMA's PRIME scheme

More from Europe

More from Geography